title: Treatment of dilated pores with 1410-nm fractional erbium-doped fiber laser.
abstract: Dilated pores can be an early sign of skin aging and are a significant cosmetic concern. The 1410-nm wavelength is optimal for superficial dermal treatments up to 650 μm deep. The aim of the present study was to evaluate the clinical effectiveness and safety of the fractional erbium-doped fiber 1410-nm laser in the treatment of dilated pores. Fifteen patients with dilated facial pores underwent three laser treatments at 3-week intervals. Posttreatment skin responses and side effects were assessed at treatment and follow-up visits by study physicians. Clinical effectiveness of treatment was assessed by both study physicians and patients 3 months after the final laser treatment using a quartile grading scale. Histological examination was performed using biopsy samples taken at baseline (pretreatment) and 3 months after the last treatment. This study showed that greater than 51 % improvement in dilated pores was demonstrated in 14 of 15 patients after three sessions of laser treatments. Improvements in skin texture, tone, and smoothness were reported in all patients. Treatment was well tolerated in all patients, with no unanticipated side effects. This study demonstrates that the 1410-nm fractional erbium fiber laser is effective and safe for treatment of dilated facial pores in Fitzpatrick skin types III-IV.
authors: Arumdaun Nara Dermatologic Clinic, Seoul, Korea.
authors: Dong-Hye
authors: DH
authors: Suh
authors: Ka-Yeun
authors: KY
authors: Chang
authors: Sang-Jun
authors: SJ
authors: Lee
authors: Kye-Yong
authors: KY
authors: Song
authors: Jeong Hwee
authors: JH
authors: Choi
authors: Min Kyung
authors: MK
authors: Shin
authors: Ki-Heon
authors: KH
authors: Jeong
mesh_terms: D000328:Adult; D004871:Erbium / Q000737:chemistry; D005145:Face / Q000528:radiation effects; D005260:Female; D006801:Humans; D053844:Lasers, Solid-State; D028022:Low-Level Light Therapy; D008297:Male; D008875:Middle Aged; D015595:Skin Aging / Q000528:radiation effects*; D012871:Skin Diseases / Q000532:radiotherapy*; D016896:Treatment Outcome
chemical_list: D004871:Erbium
references: Dermatol Surg. 2000 Jul;26(7):649-52
references: 10886272
references: Dermatol Surg. 2009 Jan;35(1):108-14
references: 19076205
references: Dermatol Surg. 1999 Jan;25(1):18-22
references: 9935087
references: Lasers Surg Med. 2006 Feb;38(2):142-9
references: 16392146
references: Br J Dermatol. 2006 Nov;155(5):890-4
references: 17034515
references: Dermatology. 2005;210(1):3-7
references: 15604536
references: Dermatol Surg. 2000 Sep;26(9):835-42; discussion 843
references: 10971556
references: Arch Dermatol. 2002 Nov;138(11):1486-93
references: 12437455
references: Photodermatol Photoimmunol Photomed. 2009 Dec;25(6):328-30
references: 19906169
references: J Dermatolog Treat. 2010 Jul;21(4):258-60
references: 20509817
references: Skin Pharmacol Appl Skin Physiol. 2000 Nov-Dec;13(6):372-89
references: 11096379
references: J Dermatolog Treat. 2009;20(4):223-8
references: 19125363
references: Lasers Med Sci. 2010 Jan;25(1):137-44
references: 19787413
references: Lasers Surg Med. 2006 Mar;38(3):169-76
references: 16532440
references: Skin Pharmacol Appl Skin Physiol. 2003 Sep-Oct;16(5):324-42
references: 12907837